Internal Medicine, Gastroenterology · Indianapolis, IN
NPI
1891876785
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1701 N Senate Blvd
Indianapolis, IN, 46202
Phone (888) 484-3258
Groups this clinician bills Medicare through
Medicare paid, 2024
$20K
216 services
Medicare patients, 2024
151
Average age 68
Drug cost, 2024
$872K
1,194 prescriptions
Company payments, 2025
$171
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas V Nowak was code 99213 (office e&m - established), 40 times for 37 patients. In total Thomas V Nowak billed 216 services in 21 codes, and Medicare paid $20K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Facility | 40 | 37 | $40.75 | $1,630 |
| 99214 Office E&M - Established | Facility | 22 | 22 | $65.16 | $1,433 |
| 45385 Colonoscopy - Lesion Removal | Facility | 19 | 19 | $192.39 | $3,655 |
| 99213 Office E&M - Established | Office | 18 | 16 | $62.46 | $1,124 |
| 99214 Office E&M - Established | Office | 16 | 15 | $89.88 | $1,438 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 16 | 16 | $165.89 | $2,654 |
| 99215 Office E&M - Established | Facility | 13 | 12 | $98.72 | $1,283 |
By year: 2022 $22K for 242 services; 2023 $20K for 227 services; 2024 $20K for 216 services.
Medicare prescription drug claims, 2024
In 2024, the drug Thomas V Nowak prescribed most often to Medicare patients was Promethazine Hcl, with 187 prescriptions and refills. In total Thomas V Nowak wrote 1,194 Medicare prescriptions that cost $872K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Promethazine Hcl Generic | 187 | 207 | 42 | $10K |
| Omeprazole Generic | 146 | 331 | 43 | $4,654 |
| Famotidine Generic | 129 | 338 | 44 | $3,023 |
| Dronabinol Generic | 80 | 81 | 15 | $20K |
| Linzess Linaclotide | 71 | 109 | 16 | $58K |
| Ondansetron Odt Ondansetron | 57 | 67 | 18 | $3,777 |
| Pantoprazole Sodium Generic | 51 | 123 | 19 | $1,278 |
| Esomeprazole Magnesium Generic | 50 | 98 | 13 | $1,325 |
| Dicyclomine Hcl Generic | 44 | 62 | 11 | $1,008 |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 42 | 42 | 42 | $635 |
| Lubiprostone Generic | 24 | 34 | Under 11 | $1,829 |
| Creon Lipase/Protease/Amylase | 22 | 29 | Under 11 | $80K |
| Ondansetron Hcl Generic | 21 | 29 | Under 11 | $442 |
| Granisetron Hcl Generic | 20 | 21 | Under 11 | $18K |
| Colesevelam Hcl Generic | 19 | 37 | Under 11 | $2,939 |
Brand drugs: - claims; generic drugs: 924 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas V Nowak $171 ($171 in general payments such as food, travel and fees) from 1 company. The largest payer was Enterra Medical, Inc. with $171.
| Company | Payments | Amount |
|---|---|---|
| Enterra Medical, Inc. | 1 | $171 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.